X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

From Hope to Cures: The Value of Biopharmaceutical Innovation

By Ieva M. Augstums  |    August 20, 2015
Biopharmaceutical innovation means more than helping patients lead longer, healthier, more productive lives. Through the continued development of new treatments and cures, each discovery...   Read More

Biopharmaceutical Innovation Benefits Many Sectors of Industry

By PhRMA Staff  |    July 8, 2015
While the connection between sectors isn’t obvious to many, the sheet metal industry plays an integral role in the development of new medicines. Without it, many innovative new treatment options...   Read More

PhRMA Member Companies Invested $51.2 Billion in R&D in 2014

By John Castellani  |    April 20, 2015
Earlier today, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced that its member companies have invested more than $600 billion in the search for new treatments and cures...   Read More

A Life-Saving Life’s Work: A Story on the Impact of Clinical Trials

By Guest Contributor  |    March 23, 2015
Clinical trials are an essential step in the process to develop new medicines and as they work to bring about lifesaving new treatments, they also contribute to the local economies where they are...   Read More

Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending

By Mark Grayson  |    March 23, 2015
The biopharmaceutical industry comes out on top as the country’s manufacturing leader in innovation and economic contributions in a new report from ndp | analytics. According to the analysis, the...   Read More

New Report: Clinical Trials and the Impact on State Economies

By John Corea  |    March 12, 2015
Beyond the profound value that biopharmaceutical industry research and development (R&D) brings patients – new treatments and potential cures for society’s most devastating and costly diseases –...   Read More

Maintaining Appropriate Incentives for Biopharmaceutical Innovation

By Anne McDonald Pritchett, PhD  |    February 4, 2015
As we enter the second half of the decade, the biopharmaceutical industry’s approach to research and development (R&D) continues to evolve to meet the growing demand for new medicines. New...   Read More

Why the World Looks to the U.S. for the Most Elusive Cures

By Robert Zirkelbach  |    February 3, 2015
Research and development (R&D) is the backbone of the biopharmaceutical industry and the reason why we have seen more than 450 new medicines approved in the U.S. since 2000 to help fight cancer,...   Read More

The Industry-Labor Partnership: Where Biopharmaceutical Innovation Meets Economic Advancement

By Scott LaGanga  |    January 28, 2015
As someone who grew up around the biopharmaceutical industry and knows firsthand the impact that it has on local communities, I’m frequently reminded of our members’ far-reaching impact in my role as...   Read More

Castellani and Molineaux OpEd in Patriot News

By PhRMA Staff  |    March 4, 2011
The oped by John Castellani, PhRMA's President and CEO, and Chris Molineaux, President of Pennsylvania BIO, in the March 4 Patriot News in Pennsylvania is worth a look. Some key passages:   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates